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The Shelhigh NR-2000C is a totally biologic
stentless conduit designed for the treatment
of various aortic root pathologies. After im-
planting 115 conduits, 7 patients presented
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Thierry Carrel reports terminating a previous
relationship with Shelhigh.
Received for publication Aug 22, 2007;
accepted for publication Sept 11, 2007.
Address for reprints: Thierry P. Carrel, MD,
Department of Cardiovascular Surgery, Uni-
versity Hospital, CH-3010 Berne, Switzer-
land (E-mail: thierry.carrel@insel.ch).
J Thorac Cardiovasc Surg 2008;136:52-7
0022-5223/$34.00
Copyright  2008 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.09.04752 The Journal of Thoracic and CardObjective: The implantation of a composite graft is the treatment of choice for patients
with aortic root disease if the valve cannot be preserved and the patient is not a suitable
candidate for a Ross procedure. Several years ago, the Shelhigh NR-2000C (Shelhigh,
Inc, Millburn, NJ) was introduced in Europe. Being a totally biologic conduit and con-
sidering the lack of homografts, the graft seemed an ideal conduit for patients with
destructive endocarditis, as well as for older patients who were not suitable candidates
for oral anticoagulation.
Methods: From 2001 until 2006, the Shelhigh NR-2000C stentless valved conduit
was implanted in 115 patients for various aortic root pathologies. The conduit consists
of a bovine pericardial straight graft with an incorporated porcine stentless valve.
Aortic root repair was performed during standard cardiopulmonary bypass and mild
hypothermia in the majority of patients. Deep hypothermic circulatory arrest com-
bined with selective antegrade cerebral perfusion was used when the repair extended
into the arch.
Results: Seven patients with uncomplicated early outcome presented with unexpected
sudden disastrous findings at the level of the aortic root, although 1-year follow-up
computed tomographic scans were normal. Four of these patients underwent emer-
gency operations because of desintegration of the graft, along with rupture of the aor-
tic root. Retrospectively, the main findings were persistent fever or subfebrility over
months and a halo-like enhancement on computed tomographic scans. Extensive
microbiologic examinations were performed without finding a causative organism.
Conclusion: The use of the Shelhigh aortic stentless conduit can no longer be advo-
cated, and meticulous follow-up of patients in whom this device has been implanted
has to be recommended.
T
he implantation of a composite graft is the treatment of choice for patients with
aortic root disease when the valve cannot be repaired or reimplanted by using
the David procedure and when the patient is not a suitable candidate for a pul-
monary autograft procedure.1-4 Several years ago, a new xenopericardial conduit
(Shelhigh, Inc, Millburn, NJ) was introduced in Europe.5,6 The Shelhigh conduit
NR-2000C consists of a bovine pericardial straight graft with an incorporated porcine
stentless valve. It is preserved in a special process, called No-React by the manufac-
turer, meaning it is glutaraldehyde cross-linked, detoxified, and heparin treated with
the aim of less calcification and tissue deterioration in the long term.7-9 We present
here some alarming, if not deleterious, signs of conduit malfunction that required
reoperation or were most probably responsible for the patient’s death.
Materials and Methods
Patients
The Shelhigh stentless valved conduit was implanted in 115 patients between 2001 and March
2006 for various aortic root pathologies. The initial clinical experience was satisfactory; iniovascular Surgery c July 2008
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CT 5 computed tomography
FDA 5 US Food and Drug Administration
particular, hemostatic and hemodynamic properties were encourag-
ing. Being a totally biologic conduit and considering the lack of
homografts, the Shelhigh graft seemed an ideal conduit for patients
with destructive endocarditis, as well as for older patients who do
not want lifelong oral anticoagulation.10-13
Device
The Shelhigh stentless aortic valve conduit is a totally biologic con-
duit available in sizes between 21 and 31 mm. Rinsing is not re-
quired. The conduit and the valve are glutaraldehyde cross-linked,
detoxified, and heparin treated with No-react. This proprietary de-
toxification process eliminates residual glutaraldehyde and ensures
stable tissue cross-linking with less calcification and tissue deterio-
ration in the long term.7-9 After achieving preservation, individual
noncoronary porcine cusps are selected and fitted on a scallop-
shaped tubular bovine pericardium. This assembly satisfies the
hemodynamic requirements for flexibility and strength. The 150-mm-
long pericardial cuff can be trimmed appropriately for each case and
facilitates repair when complete repair of the ascending aorta is re-
quired. In vitro hemodynamics have been described as excellent,
with ideal coaptation of the leaflets. Laboratory testing performed
in a pulse duplicator evaluated the stentless valve in the fresh aortic
root; at all flow rates, the stentless valve showed uniformly higher
effective orifice areas and better hemodynamics than the similar
valve with a ring. These tests confirmed that the ring transfers the
stress from the commissures to the aortic valve.14,15
Surgical Technique
Aortic root repair is performed during standard cardiopulmonary by-
pass and mild hypothermia in the majority of patients. Deep hypo-
thermic circulatory arrest combined with selective antegrade
cerebral perfusion is used when the repair extends into the aortic
arch. The diseased aortic root and ascending aorta are completely re-
moved, and the coronary ostia are excised with a small rim of sur-
rounding aortic tissue. After sizing the aortic anulus with Shelhigh
sizers, a valved conduit 1 or 2 sizes larger is implanted. The proxi-
mal annulus anastomosis is performed by using either continuous
4-0 polypropylene sutures or interrupted mattress 2-0 Ethibond su-
tures (Ethicon, Somerville, NJ). The coronary ostia are reimplanted
into the conduit by using the button technique with 5-0 or 6-0 run-
ning monofilament sutures. Finally, the distal anastomosis is per-
formed with 4-0 running polypropylene sutures (Figures 1 and 2).
Results
Postoperative Course
Unfortunately, there has been increasing concern about dele-
terious midterm outcomes in several patients in our single-
center experience. We present 7 patients with uncomplicated
early outcomes after aortic root replacement: 4 of them pre-
sented with unexpected sudden disastrous findings at theThe Journal of Tlevel of the aortic root, although the 1-year follow-up com-
puted tomographic (CT) scans were normal. These 4 patients
underwent conduit exchange because of desintegration of ei-
ther proximal or coronary anastomoses. The main findings
were persistent fever or subfebrile condition for months
and a halo-like enhancement around the conduit on CT scans.
Because we first suspected severe infective endocarditis of
the graft extensive testing and evaluation of the graft material
and patient’s blood was performed. Considering the utterly
strange intraoperative findings and the nature of the graft, we
even considered bovine microorganisms, without finding
a causativeorganism.Noneof thesepatientsunderwent primary
implantation of the graft because of native valve endocarditis.
Figure 1. Implantation sequence of the Shelhigh conduit in a
complex redo case. Left coronary is re-implanted (With permis-
sion of J Heart Valve Dis).
Figure 2. Final view of the Shelhigh conduit in a complex redo
case, following distal anastomosis (With permission of J Heart
Valve Dis).horacic and Cardiovascular Surgery c Volume 136, Number 1 53
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graft because of annuloaortic ectasia with aortic valve insuf-
ficiency. One year later, emergency reoperation was neces-
sary because of rapid deterioration of the general condition
and severe dyspnea of New York Heart Association func-
tional class IV. CT scans showed a completely destroyed aor-
tic root and suspicion of ventriculoaortic disconnection. The
intraoperative findings confirmed these previous findings and
showed complete destruction of the aortic root; the proximal
anastomosis, which had been performed with interrupted,
pledget-reinforced sutures, was ruptured, as well as both cor-
onary anastomoses (Figure 3) 3 months before CT was com-
pletely normal in this patient (Figure 4). A brownish
gelatinous material was found at the level of the remnants
of the native annulus. Because we were suspecting a fulmi-
nant endocarditis and because the implantation of a new aor-
tic root prosthesis required intraventricular sutures, we
implanted a new Shelhigh composite graft. The patient
made an uneventful recovery and died 5 months later of aor-
tic rupture, despite a normal 3-month follow-up CT scan.
Patient 2 presented with high transvalvular gradient but
normal leaflet motion 1 year after implantation of a Shelhigh
stentless valve because of aortic valve stenosis. Re-explora-
tion showed a partial destruction of the aortic root, which
had not been seen before. The aortic root had to be replaced,
and we used a Shelhigh conduit. One year later, the patient
presented with severe dyspnea. Echocardiography showed
moderate aortic insufficiency, severe mitral valve regurgita-
tion, and aortic root rupture at the level of the right coronary
sinus. Emergency reoperation showed a huge false aneurysm
with destruction of the aortomitral continuity, whereas the
right coronary artery ostium and the distal graft to the native
aortic anastomosis were completely dehiscent. A second at-
tempt to replace the destroyed aortic root was not successful,
Figure 3. Complete destruction of the aortic root 1 year after
conduit implantation because of annuloaortic ectasia.54 The Journal of Thoracic and Cardiovascular Surgery c Julyand the patient could not be weaned from cardiopulmonary
bypass. She died in the operating theater after hours of recon-
structive surgery.
Patient 3 underwent composite graft implantation because
of annuloaortic ectasia with a bicuspid aortic valve. Because
subfebrile temperature persisted for weeks after the opera-
tion, a close follow-up was performed. Two years later,
a pseudoaneurysm of the aortic root was suspected. Re-ex-
ploration showed impressive destruction of the pericardial
tube, dehiscent sutures of the coronary arteries, and a perfused
pseudoaneurysm, representing a contained rupture at the
level of the aortic annulus (Figures 5–8). In this case, too,
a lot of brownish material was found close to the stentless
valve tube, but no microorganisms could be detected in serial
microbiologic examinations. An aortic homograft was
Figure 4. Same patient as in Fig 3 with normal CT scan 3 months
before.
Figure 5. Follow-up computed tomographic scan of patient 3 with
periaortic reaction, but no sign of disfunction of the conduit.2008
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plantation of the coronary ostia had to be performed by using
saphenous vein graft interposition because the coronary but-
tons were completely necrotic.
Patient 4 presented with aortic root dilation, severe aortic
valve regurgitation, and dilation of the aortic arch. She under-
went implantation of a Shelhigh composite graft with replace-
ment of the ascending aorta, as well the arch, with a prosthetic
aortic graft. CT scanning and echocardiographic analysis per-
formed 6 months later showed normal postoperative condi-
tions. (Figure 9) Right before the 1-year follow-up the
patient presented with fever for weeks. Another CT scan
Figure 7. Intraoperative view of destroyed aortic root and dis-
solved conduit in patient 3.
Figure 6. Computed tomographic scan of patient 3 one year later
with perfused pseudoaneurysm of the aortic root.The Journal of Thwas performed and showed enhancement around the proxi-
mal anastomosis and a impressive halo-like appearance (Fig-
ure 10). One week later, re-exploration was performed
Figure 8. The valve was normal in patient 3 but the conduit com-
pletely dissolved.
Figure 9. CT scan of patient 4, 6 months postoperatively.oracic and Cardiovascular Surgery c Volume 136, Number 1 55
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the level of the proximal aortic annular anastomosis. Re-ex-
ploration showed a completely necrotic annulus. The root
was reconstructed by using a homograft and a saphenous
vein graft for interposition to the left coronary artery.
We have to claim 3 unexplained deaths in 3 additional pa-
tients (patients 5–7) in the first 2 years after implantation of
a Shelhigh stentless tube valved graft. Review of the fol-
low-up CT scans showed a halo-like enhancement at the level
of the root in every patient. Necropsy was performed in 1 pa-
tient and demonstrated findings very similar to those found in
the reoperated patient. One patient was referred with a rupture
at the level of the aortic root with a huge hematoma extending
into the arch but was no longer a surgical candidate because
of advanced age. He was transferred to another hospital and
died a few days later, most probably from aortic root rupture.
Discussion
Several technical options can be used to repair or replace the
aortic root. In addition to aortic valve–sparing techniques,
composite grafts, including a mechanical valve and, more
rarely, the pulmonary autograft, are the most commonly
used material for this purpose.1-4 Traditional glutaralde-
hyde-treated valves tend to calcify, especially in younger
patients. The No-React detoxification process eliminates re-
sidual glutaraldehyde and ensures stable tissue cross-linking.
In vitro results on reducing calcification and tissue deteriora-
tion have been encouraging.7,8 There has been limited pub-
lished clinical experience with this new valved conduit so
far. Preliminary reports showed satisfactory results, espe-
cially when the conduit was implanted because of destructive
aortic valve endocarditis.14 The stentless valved tube graft
demonstrated similar results as cryopreserved homografts
Figure 10. CT scan of patient 4, 6 months after figure 9 shows
increasing peri-aortic reaction.56 The Journal of Thoracic and Cardiovascular Surgery c Julyin terms of ease of implantation, perioperative mortality,
cure of infection, and hemodynamic characteristics.
Our first experience confirmed that the Shelhigh stentless
valved conduit was easy to handle and showed excellent early
hemodynamic characteristics. The material was highly hemo-
static because there was no bleeding from stitches through the
pericardial tissue. There are no fabric or mechanical compo-
nents that would make this conduit ideal for the treatment of
the infected aortic root when homografts are not available.
The pericardial tube allows for nearly unlimited distal aortic
repair. In older patients this conduit was thought to be an ex-
cellent alternative to a composite graft with a mechanical
valve because long-term anticoagulation is not required.
However, despite our favorable initial evaluation of this
biologic conduit, we observed some deleterious findings in
several patients during short-term and midterm follow-up
that forced us to interrupt further use of this device. We
had repetitive correspondence with the chief scientific officer
of the company, but he was not able to provide us with sub-
stantial information regarding our observations.16 Moreover,
he suspected endocarditis of the conduit or technical failure
during initial implantation, which would have resulted in
pseudoaneurysm formation. Because no patients had positive
blood culture results and the first postoperative CT scans 3 to
6 months following surgery were normal, we could not
accept these reasons to explain the observed problems.
The company assured us that there was no report on sim-
ilar events thus far. For this reason, we were hesitant to under-
take steps in terms of a formal report and considered
endocarditis as the most likely cause. Some time later, we for-
tunately discovered that 2 warning letters had already been
issued by the US Food and Drug Administration (FDA) in
2000 and 2003 complaining about the manufacturing stan-
dards of the company.17,18
On April 19, 2007, the FDA published a preliminary pub-
lic health notification on possible contamination and mal-
function of devices manufactured by Shelhigh, Inc. A few
days later, the FDA seized all medical products from
the device manufacturer for significant violations because
the company declined the voluntary recall recommended
by the FDA.19
Since then, we stopped using Shelhigh products and are
expecting additional information about this unclear and un-
satisfying situation. In the meantime, we cannot advocate
the use of the Shelhigh aortic stentless conduit and recom-
mend meticulous clinical and imaging follow-up of patients
in whom this device has been implanted.
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Recently, a tricky case was presented by the group of Hans Scheld in Munster.20 The paper focused on the creation of a self-
made total artificial heart using different components of available ventricular assist devices following partial resection of the
heart. However, the primary problem of this patient was the failure of a Shelhigh aortic valved conduit (Shelhigh Inc, NJ,
USA) implanted a few months earlier in the setting of acute type A aortic dissection.
Most probably, the authors were at that time not aware of this rare but disastrous complication which has been encountered by
others but unfortunately has not been reported in the literature before. The case reported by Tjan and co-authors have strong sim-
ilarity to our cases. The aortic stenosis was probably not due to early degeneration of the valve but due to compression of the valve
by an extravasation. Fortunatelywe did not experience any perforation of the root into the right ventricle but this complication fits
very well in the spectrum of problems we have observed. The case described by Tjan and colleagues required nearly 6 months of
hospitalization, biventricular assist device and finally cardiac transplantation to manage severe problems caused by a deficient
implant.
We had repetitive correspondance with the Chief Scientific Officer of the company but no substantial informations regarding
our observations were provided. The company still assured us that there was no report on similar events so far. For this reason,
we were hesitant to undertake steps in terms of a formal report and considered endocarditis as the most likely cause.
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